Anil Andani, MD
Family Practice · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 10 years
- Graduated 2016
Offices
1 location · Community Medical Centers, Inc. · 47 clinicians in this group
Hospitals listed: St Joseph'S Medical Center of Stockton. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Andani’s office at (209) 507-7000 to ask if they take your plan before you enroll.
State licence records
1 licence
- Illinois 125069840Temporary Medical Permit · since 2017 · expires 2020-06-30Specialty on the licence: Family MedicineExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Medicaid work
$295,847 in 2024
Medicaid paid $295,847 for 9,774 billed services this clinician did in 2024, up to 172 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,964 | $288,560 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 1,525 | $3,522 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 215 | $1,527 |
| Return visit (30+ min) | 2,231 | $844 |
| Short return visit (20+ min) | 997 | $643 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 58 | $465 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 20 | $286 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 775 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 136 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 31 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 637 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 318 | $0 |
| 2024 | 9,774 | 18 | 172 | $295,847 |
| 2023 | 17,568 | 20 | 363 | $554,524 |
| 2022 | 15,828 | 20 | 409 | $494,516 |
| 2021 | 13,666 | 22 | 332 | $492,243 |
| 2020 | 1,756 | 12 | 280 | $113,340 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 3,749 | $538,398 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 2,024 | $5,817 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 454 | $2,705 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 208 | $2,333 |
| Return visit (30+ min) | 4,257 | $2,312 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 106 | $1,592 |
| Short return visit (20+ min) | 2,268 | $762 |
| Hemoglobin A1C level | 79 | $333 |
| New patient visit (45+ min) | 39 | $165 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 257 | $105 |
| Blood glucose (sugar) level | 175 | $3 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 1,018 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 3,412 | $477,028 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 675 | $4,504 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 1,370 | $3,908 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 390 | $3,563 |
| Return visit (30+ min) | 3,052 | $2,903 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 87 | $1,241 |
| Short return visit (20+ min) | 3,167 | $1,062 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 170 | $123 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 68 | $72 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 13 | $65 |
| Bilateral quantitative screening test of visual acuity | 24 | $46 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 1,067 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 3,460 | $475,668 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 655 | $3,005 |
| Return visit (30+ min) | 2,586 | $3,002 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 1,317 | $2,626 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 344 | $2,518 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 166 | $2,164 |
| Short return visit (20+ min) | 2,536 | $1,810 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 23 | $889 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 126 | $226 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years | 23 | $137 |
| New patient visit (45+ min) | 41 | $83 |
| Short return visit | 26 | $72 |
2020
| Clinic visit/encounter, all-inclusive | 810 | $111,177 |
| Short return visit (20+ min) | 360 | $783 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 67 | $423 |
| Return visit (30+ min) | 103 | $297 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 42 | $286 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 109 | $175 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 188 | $131 |
| OFFICE/OUTPATIENT VISIT NEW | 18 | $69 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 15 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 13 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 18 | $0 |
| Blood glucose (sugar) level | 13 | $0 |
Drugs they prescribed that Part D paid
$297,212
Pharmacies billed $297,212 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (13 of 2,614) in 2024. At or below the middle of the specialty; the typical family practice clinician is at 2%.
2,092 generic and 489 brand-name prescriptions · $297,212 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Synjardy | 79 | $66,096 | $837 |
| Jardiance | 45 | $45,618 | $1,014 |
| Rybelsus | 32 | $34,990 | $1,093 |
| Tradjenta | 28 | $17,754 | $634 |
| Ozempic | 18 | $17,616 | $979 |
See all 54 drugs
| Synjardy | 79 | $66,096 | $837 |
| Jardiance | 45 | $45,618 | $1,014 |
| Rybelsus | 32 | $34,990 | $1,093 |
| Tradjenta | 28 | $17,754 | $634 |
| Ozempic | 18 | $17,616 | $979 |
| Januvia | 13 | $14,631 | $1,125 |
| Eliquis | 20 | $12,326 | $616 |
| Dulera | 23 | $8,609 | $374 |
| Spiriva Respimat | 15 | $7,661 | $511 |
| Basaglar Kwikpen U-100 | 12 | $5,454 | $455 |
| Symbicort | 12 | $2,739 | $228 |
| Atorvastatin | 344 | $2,482 | $7 |
| Lantus Solostar | 25 | $2,282 | $91 |
| Hydroxyzine | 32 | $1,056 | $33 |
| Ezetimibe | 40 | $1,011 | $25 |
| Lisinopril | 152 | $965 | $6 |
| Gabapentin | 94 | $959 | $10 |
| Levothyroxine | 72 | $897 | $12 |
| Albuterol Sulfate Hfa | 42 | $851 | $20 |
| Ventolin Hfa | 16 | $786 | $49 |
| Losartan | 118 | $765 | $6 |
| Amlodipine Besylate | 153 | $710 | $5 |
| Nifedipine Er | 24 | $687 | $29 |
| Tamsulosin | 47 | $585 | $12 |
| Losartan-Hydrochlorothiazide | 47 | $553 | $12 |
| Metoprolol | 36 | $517 | $14 |
| Quetiapine | 12 | $442 | $37 |
| Metformin | 66 | $434 | $7 |
| Famotidine | 81 | $410 | $5 |
| Fluticasone Propionate | 36 | $350 | $10 |
| Levetiracetam | 19 | $325 | $17 |
| Clopidogrel | 22 | $304 | $14 |
| Hydrocodone-Acetaminophen | 12 | $291 | $24 |
| Pantoprazole | 19 | $285 | $15 |
| Omeprazole | 52 | $282 | $5 |
| Hydrocortisone | 13 | $263 | $20 |
| Carvedilol | 23 | $242 | $11 |
| Ammonium Lactate | 14 | $239 | $17 |
| Allopurinol | 23 | $236 | $10 |
| Duloxetine | 22 | $216 | $10 |
| Diclofenac | 13 | $209 | $16 |
| Metoprolol | 39 | $206 | $5 |
| Hydrochlorothiazide | 58 | $204 | $4 |
| Buspirone | 12 | $202 | $17 |
| Alendronate | 22 | $202 | $9 |
| Montelukast | 17 | $113 | $7 |
| Sertraline | 33 | $109 | $3 |
| Oxybutynin Chloride | 12 | $95 | $8 |
| Simvastatin | 26 | $93 | $4 |
| Lisinopril-Hydrochlorothiazide | 22 | $92 | $4 |
| Chlorthalidone | 12 | $83 | $7 |
| Furosemide | 35 | $53 | $2 |
| Meloxicam | 19 | $27 | $1 |
| Ibuprofen | 11 | $17 | $2 |
Year by year
| 2024 | 2,614 | 216 | 1% (13) | 19% | $297,212 |
| 2023 | 2,603 | 188 | 1% (14) | 18% | $333,796 |
| 2022 | 2,516 | 161 | 1% (19) | 17% | $225,150 |
| 2021 | 1,769 | 115 | 1% (15) | 18% | $127,193 |
| 2020 | 217 | 45 | None | None | $13,740 |
| 2019 | 61 | 20 | 0% (0) | None | $3,440 |
| 2018 | 89 | 37 | None | None | $2,202 |
| 2017 | 18 | None | None | None | $2,117 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 49 drugs
| Jardiance | 69 | $68,110 | $987 |
| Rybelsus | 28 | $34,545 | $1,234 |
| Januvia | 18 | $22,285 | $1,238 |
| Synjardy | 26 | $18,417 | $708 |
| Tradjenta | 22 | $18,092 | $822 |
| Ozempic | 16 | $16,095 | $1,006 |
| Symbicort | 24 | $9,738 | $406 |
| Atorvastatin | 328 | $9,566 | $29 |
| Advair Diskus | 22 | $8,524 | $387 |
| Basaglar Kwikpen U-100 | 16 | $5,655 | $353 |
| Lisinopril | 199 | $3,187 | $16 |
| Amlodipine Besylate | 171 | $2,569 | $15 |
| Gabapentin | 99 | $2,485 | $25 |
| Losartan | 131 | $2,238 | $17 |
| Ventolin Hfa | 18 | $1,480 | $82 |
| Levothyroxine | 80 | $1,403 | $18 |
| Metformin | 105 | $1,323 | $13 |
| Tamsulosin | 54 | $1,233 | $23 |
| Albuterol Sulfate Hfa | 44 | $1,212 | $28 |
| Levetiracetam | 26 | $1,172 | $45 |
| Omeprazole | 64 | $1,169 | $18 |
| Nifedipine Er | 21 | $1,074 | $51 |
| Pantoprazole | 28 | $1,071 | $38 |
| Ezetimibe | 19 | $1,063 | $56 |
| Losartan-Hydrochlorothiazide | 32 | $1,022 | $32 |
| Nano 2nd Gen Pen Needle | 13 | $989 | $76 |
| Famotidine | 34 | $836 | $25 |
| Hydrochlorothiazide | 89 | $686 | $8 |
| Carvedilol | 25 | $631 | $25 |
| Pregabalin | 12 | $599 | $50 |
| Metoprolol | 27 | $589 | $22 |
| Simvastatin | 29 | $520 | $18 |
| Alendronate | 16 | $500 | $31 |
| Ammonium Lactate | 20 | $499 | $25 |
| Duloxetine | 19 | $482 | $25 |
| Hydroxyzine | 15 | $461 | $31 |
| Sertraline | 37 | $438 | $12 |
| Furosemide | 31 | $392 | $13 |
| Allopurinol | 23 | $382 | $17 |
| Buspirone | 11 | $378 | $34 |
| Metoprolol | 33 | $350 | $11 |
| Naproxen | 27 | $344 | $13 |
| Clopidogrel | 24 | $341 | $14 |
| Oxybutynin Chloride | 13 | $300 | $23 |
| Tramadol | 13 | $276 | $21 |
| Diclofenac | 12 | $238 | $20 |
| Hydralazine | 13 | $237 | $18 |
| Spironolactone | 13 | $126 | $10 |
| Meloxicam | 14 | $71 | $5 |
2022: 48 drugs
| Jardiance | 42 | $34,949 | $832 |
| Januvia | 39 | $27,249 | $699 |
| Tradjenta | 32 | $24,683 | $771 |
| Eliquis | 24 | $15,784 | $658 |
| Xarelto | 12 | $11,043 | $920 |
| Advair Diskus | 24 | $9,022 | $376 |
| Symbicort | 19 | $7,452 | $392 |
| Atorvastatin | 341 | $5,202 | $15 |
| Basaglar Kwikpen U-100 | 12 | $4,230 | $353 |
| Flovent Hfa | 13 | $3,688 | $284 |
| Albuterol Sulfate Hfa | 40 | $2,160 | $54 |
| Nifedipine Er | 24 | $2,066 | $86 |
| Ventolin Hfa | 17 | $1,721 | $101 |
| Lisinopril | 173 | $1,611 | $9 |
| Tamsulosin | 65 | $1,454 | $22 |
| Amlodipine Besylate | 188 | $1,361 | $7 |
| Losartan | 104 | $1,308 | $13 |
| Gabapentin | 92 | $1,223 | $13 |
| Levothyroxine | 90 | $1,139 | $13 |
| Metformin | 132 | $1,007 | $8 |
| Omeprazole | 66 | $760 | $12 |
| Pantoprazole | 54 | $708 | $13 |
| Baclofen | 19 | $476 | $25 |
| Metoprolol | 24 | $469 | $20 |
| Hydrochlorothiazide | 112 | $451 | $4 |
| Losartan-Hydrochlorothiazide | 20 | $415 | $21 |
| Diclofenac | 15 | $412 | $27 |
| Carvedilol | 50 | $399 | $8 |
| Simvastatin | 31 | $349 | $11 |
| Metoprolol | 27 | $347 | $13 |
| Famotidine | 26 | $327 | $13 |
| Chlorthalidone | 13 | $317 | $24 |
| Oxybutynin Chloride | 13 | $308 | $24 |
| Glimepiride | 12 | $292 | $24 |
| Fluticasone Propionate | 23 | $268 | $12 |
| Allopurinol | 15 | $206 | $14 |
| Alendronate | 19 | $205 | $11 |
| Furosemide | 24 | $166 | $7 |
| Rosuvastatin | 12 | $151 | $13 |
| Clopidogrel | 14 | $128 | $9 |
| Tramadol | 13 | $122 | $9 |
| Spironolactone | 11 | $108 | $10 |
| Propranolol | 15 | $98 | $7 |
| Ibuprofen | 19 | $86 | $5 |
| Glipizide | 16 | $81 | $5 |
| Triamcinolone Acetonide | 12 | $48 | $4 |
| Naproxen | 11 | $36 | $3 |
| Sertraline | 13 | $31 | $2 |
2021: 38 drugs
| Eliquis | 21 | $13,991 | $666 |
| Tradjenta | 19 | $13,951 | $734 |
| Januvia | 22 | $9,005 | $409 |
| Xarelto | 13 | $6,740 | $518 |
| Advair Diskus | 15 | $5,838 | $389 |
| Levemir | 14 | $5,570 | $398 |
| Symbicort | 14 | $5,371 | $384 |
| Flovent Hfa | 18 | $4,698 | $261 |
| Basaglar Kwikpen U-100 | 12 | $4,139 | $345 |
| Atorvastatin | 222 | $2,638 | $12 |
| Nifedipine Er | 19 | $1,842 | $97 |
| Ventolin Hfa | 14 | $1,639 | $117 |
| Albuterol Sulfate Hfa | 37 | $1,599 | $43 |
| Lisinopril | 111 | $974 | $9 |
| Levetiracetam | 18 | $831 | $46 |
| Tamsulosin | 33 | $792 | $24 |
| Pantoprazole | 73 | $754 | $10 |
| Losartan | 60 | $653 | $11 |
| Gabapentin | 74 | $653 | $9 |
| Metformin | 105 | $643 | $6 |
| Propranolol | 63 | $593 | $9 |
| Amlodipine Besylate | 90 | $580 | $6 |
| Diclofenac | 26 | $575 | $22 |
| Metoprolol | 18 | $543 | $30 |
| Levothyroxine | 52 | $450 | $9 |
| Glimepiride | 57 | $438 | $8 |
| Losartan-Hydrochlorothiazide | 12 | $409 | $34 |
| Omeprazole | 54 | $347 | $6 |
| Hydrochlorothiazide | 55 | $286 | $5 |
| Fluticasone Propionate | 15 | $193 | $13 |
| Carvedilol | 34 | $187 | $5 |
| Hydrocortisone | 13 | $168 | $13 |
| Furosemide | 24 | $139 | $6 |
| Spironolactone | 14 | $128 | $9 |
| Famotidine | 11 | $120 | $11 |
| Glipizide | 15 | $108 | $7 |
| Metoprolol | 12 | $87 | $7 |
| Triamcinolone Acetonide | 17 | $75 | $4 |
2020: 6 drugs
| Propranolol | 19 | $160 | $8 |
| Atorvastatin | 14 | $142 | $10 |
| Pantoprazole | 19 | $131 | $7 |
| Metformin | 16 | $109 | $7 |
| Glimepiride | 13 | $96 | $7 |
| Lisinopril | 11 | $82 | $7 |
Money from drug and device companies
$318 in 2025
| 2025 | 3 | 3 | None | $318 |
| 2024 | 2 | 3 | None | $290 |
| 2023 | 1 | 2 | None | $218 |
| 2022 | 2 | 4 | None | $343 |
| 2021 | 1 | 1 | None | $15 |
| 2020 | 2 | 2 | None | $97 |
| 2019 | 4 | 9 | None | $646 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Mavyret | $122 | 1 payment
|
| Lilly USA | Zepbound | $109 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $87 | 1 payment
|
See all 3 published payments
| Xeris Pharmaceuticals | Meals · 2025-10-29 | Gvoke Hypopen | $87 |
| Lilly USA | Meals · 2025-09-17 | Zepbound | $109 |
| Abbvie | Meals · 2025-08-28 | Mavyret | $122 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $290
| Abbvie | Mavyret | $184 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $106 | 1 payment
|
2023: $218
| AbbVie | Mavyret | $218 | 2 payments
|
2022: $343
| Abbvie | Mavyret | $208 | 2 payments
|
| Novo Nordisk | Rybelsus | $135 | 2 payments
|
2021: $15
| Merck Sharp & Dohme | Gardasil 9 | $15 | 1 payment
|
2020: $97
| GlaxoSmithKline | Bexsero | $80 | 1 payment
|
| Merck Sharp & Dohme | Pneumovax 23 | $16 | 1 payment
|
2019: $646
| Novartis Pharmaceuticals | Cosentyx | $473 | 4 payments
|
| GlaxoSmithKline | Anoro Ellipta | $114 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $48 | 3 payments
|
| Phadia US | Immunocap | $11 | 1 payment
|
Professional record
- NPI
- 1679095210
- Licence
- IL 125069840Illinois 125069840: Expired
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 7210 Murray Dr, Stockton, CA, 95210
- NPI first listed
- 2017-07-15
- NPI last updated
- 2025-02-20
- NPI record certified
- 2025-02-20
This is when the NPI record was last certified, not a medical board exam.